Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab
Open Access
- 23 May 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 243, 116829
Abstract
No abstract availableKeywords
Funding Information
- China Scholarship Council (202306100051)
This publication has 27 references indexed in Scilit:
- Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation AnalysisTargeted Oncology, 2025
- A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung CancerAdvances in Therapy, 2025
- Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trialAnnals of Oncology, 2025
- 1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trialAnnals of Oncology, 2024
- Pharmacokinetics of Dexamethasone in Children and Adolescents with ObesityThe Journal of Clinical Pharmacology, 2024
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulationEuropean Journal of Cancer, 2020
- Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer centerCancer Medicine, 2020
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy VolunteersCurrent Therapeutic Research, 2020
- Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost AnalysisClinical Pharmacology & Therapeutics, 2017
- Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid TumorsCPT: Pharmacometrics & Systems Pharmacology, 2016